Correlation Between Zoetis and Merck
Can any of the company-specific risk be diversified away by investing in both Zoetis and Merck at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zoetis and Merck into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zoetis Inc and Merck Company, you can compare the effects of market volatilities on Zoetis and Merck and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zoetis with a short position of Merck. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zoetis and Merck.
Diversification Opportunities for Zoetis and Merck
Excellent diversification
The 3 months correlation between Zoetis and Merck is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Zoetis Inc and Merck Company in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Merck Company and Zoetis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zoetis Inc are associated (or correlated) with Merck. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Merck Company has no effect on the direction of Zoetis i.e., Zoetis and Merck go up and down completely randomly.
Pair Corralation between Zoetis and Merck
Considering the 90-day investment horizon Zoetis Inc is expected to generate 0.82 times more return on investment than Merck. However, Zoetis Inc is 1.22 times less risky than Merck. It trades about 0.13 of its potential returns per unit of risk. Merck Company is currently generating about -0.1 per unit of risk. If you would invest 17,143 in Zoetis Inc on June 24, 2024 and sell it today you would earn a total of 2,121 from holding Zoetis Inc or generate 12.37% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Zoetis Inc vs. Merck Company
Performance |
Timeline |
Zoetis Inc |
Merck Company |
Zoetis and Merck Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Zoetis and Merck
The main advantage of trading using opposite Zoetis and Merck positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zoetis position performs unexpectedly, Merck can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Merck will offset losses from the drop in Merck's long position.Zoetis vs. PetIQ Inc | Zoetis vs. Emergent Biosolutions | Zoetis vs. Bausch Health Companies | Zoetis vs. Neurocrine Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Complementary Tools
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Fundamental Analysis View fundamental data based on most recent published financial statements |